Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors while in the central anxious procedure, conolidine modulates alternate molecular targets. A Science Advancements analyze discovered that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://paulp470nzd7.wikilowdown.com/user